CHMP Nod For Bioprojet Pharma's Narcolepsy Therapy
This article was originally published in Scrip
Executive Summary
The EMA's CHMP has recommended granting a marketing authorisation to Bioprojet Pharma's Wakix (pitolisant) for the orphan indication of narcolepsy with or without cataplexy (sudden severe muscle weakness or loss of muscle control).